GCP
ELDN icon

GSA Capital Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

GSA Capital Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166K Buy
+42,028
New +$153K 0.01% 1571

Other funds holding ELDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
PAM
Prodigy Asset Management Omaha, Nebraska $332M AUM 10.57% 1-Year Est. Return
DSC
Daytona Street Capital Saint Louis, Missouri $137M AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
PNFS
PW Nova Financial Services Newtown, Pennsylvania $466M AUM

GSA Capital Partners's ELDN Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 42,028 shares worth $166K. The stake represents 0.01% of the portfolio and ranks #1571 among its holdings.

62 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • GSA Capital Partners held 42,028 shares of Eledon Pharmaceuticals worth $166K as of Q2 2026.
  • Eledon Pharmaceuticals was a new GSA Capital Partners position in Q2 2026.
  • Eledon Pharmaceuticals made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1571 holding.
  • 62 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.